e-learning
resources
London 2016
Sunday, 04.09.2016
Cystic fibrosis: various aspects
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Ivacaftor-as effective in clinical practice?
Ayesha Aziz (Great Yarmouth, United Kingdom), Ayesha Aziz, Julia Borowicz-Klementowicz, Helen Barker, Christopher Johnson, Nadia Shafi, Charles Haworth, Andres Floto, Uta Hill
Source:
International Congress 2016 – Cystic fibrosis: various aspects
Session:
Cystic fibrosis: various aspects
Session type:
Thematic Poster
Number:
1257
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Ayesha Aziz (Great Yarmouth, United Kingdom), Ayesha Aziz, Julia Borowicz-Klementowicz, Helen Barker, Christopher Johnson, Nadia Shafi, Charles Haworth, Andres Floto, Uta Hill. Ivacaftor-as effective in clinical practice?. Eur Respir J 2016; 48: Suppl. 60, 1257
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: What’s NEW in the 2022 ERS/ATS PFT Interpretation Statement
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Implementation of non-medical prescribing within the clinical cystic fibrosis setting
Source: International Congress 2014 – Physiotherapy and physical activity in respiratory conditions
Year: 2014
Clinical response to elexacaftor/tezacaftor/ivacaftor for cystic fibrosis patients in a compassionate use setting
Source: Virtual Congress 2020 – Clinical monitoring and new therapies for cystic fibrosis
Year: 2020
Pulmonary function tests in clinical practice
Source: Annual Congress 2013 –PG17 Diagnostic tests for paediatric pulmonologists
Year: 2013
The use of telehealth system in improving adherence to nebulised treatment in children with cystic fibrosis: Benefits and pitfalls
Source: International Congress 2014 – Cystic fibrosis: basic science, physiology and clinical aspects
Year: 2014
Clinical efficacy data for new diagnostic tool for the selection of the most effective antibiotics for patients with cystic fibrosis
Source: Virtual Congress 2020 – Microbiology and antimicrobial strategies in cystic fibrosis
Year: 2020
Modelling and simulation of experimental designs to find the best design of randomized clinical trials in a rare disease: Cystic fibrosis
Source: International Congress 2014 – Cystic fibrosis: clinical assessment and treatment
Year: 2014
Ability of lung clearance index to track changes in a routine clinical CF setting
Source: International Congress 2015 – Paediatric respiratory physiology
Year: 2015
The impact of personalised therapies on respiratory medicine
Source: Eur Respir Rev 2013; 22: 72-74
Year: 2013
Avatar acceptability: views from the Australian Cystic Fibrosis community on the use of personalised organoid technology to guide treatment decisions
Source: ERJ Open Res, 7 (1) 00448-2020; 10.1183/23120541.00448-2020
Year: 2021
Cystic fibrosis microbiology, emerging pathogens and more treatment options
Source: International Congress 2018 – PG10 Cystic fibrosis: Basic defects and clinical problems in children
Year: 2018
Assessment of NuvoAir platform use on clinical outcomes in adults with cystic fibrosis: a first Italian experience
Source: Virtual Congress 2021 – Cystic fibrosis
Year: 2021
Interpreting lung function in clinical practice
Source: Annual Congress 2006 - PG5 - Respiratory physiology: interpreting lung function in health and disease
Year: 2006
Effect of different physiotherapy devices on ventilation distribution in adults with cystic fibrosis
Source: Annual Congress 2013 –Cystic fibrosis: physiotherapy, exercise and lung function in adults and children
Year: 2013
Diagnostic efficiency of sweat conductivity testing in cystic fibrosis
Source: International Congress 2015 – Cystic fibrosis: physiology, biomarkers, microbiology and miscellaneous
Year: 2015
Revisiting α1-antitrypsin therapy in cystic fibrosis: can it still offer promise?
Source: Eur Respir J 2007; 29: 229-230
Year: 2007
Health-economic aspects of cystic fibrosis screening and therapy
Source: Eur Respir Monogr 2014; 64: 304-319
Year: 2014
Self-perceived verses electronic monitoring of adherence to nebulised treatment in children with cystic fibrosis - does the use of telehealth system improve nebulisation adherence?
Source: Annual Congress 2013 –Cystic fibrosis: basic and applied science
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept